دورية أكاديمية
Impact of genetic polymorphisms at the promoter area of IL-10 gene on tacrolimus level in Jordanian renal transplantation recipients.
| العنوان: | Impact of genetic polymorphisms at the promoter area of IL-10 gene on tacrolimus level in Jordanian renal transplantation recipients. |
|---|---|
| المؤلفون: | Khaleel B; Yarmouk University, Faculty of Science, Department of Biological Sciences, Irbid, Jordan., Yousef AM; The University of Jordan, School of Pharmacy, Department of Biopharmaceutics and Clinical Pharmacy, Amman, Jordan., Al-Zoubi MS; Yarmouk University, Faculty of Medicine, Department of Basic Medical Sciences, Irbid, Jordan., Al-Ulemat M; Royal Medical Services, Pharmacy Department, Amman, Jordan., Masadeh AA; Royal Medical Services, Pharmacy Department, Amman, Jordan., Abuhaliema A; The University of Jordan, School of Pharmacy, Department of Biopharmaceutics and Clinical Pharmacy, Amman, Jordan., Al-Batayneh KM; Yarmouk University, Faculty of Science, Department of Biological Sciences, Irbid, Jordan., Al-Trad B; Yarmouk University, Faculty of Science, Department of Biological Sciences, Irbid, Jordan. |
| المصدر: | Journal of medical biochemistry [J Med Biochem] 2022 Jul 29; Vol. 41 (3), pp. 327-334. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Society of Medical Biochemists of Serbia Country of Publication: Serbia NLM ID: 101315490 Publication Model: Print Cited Medium: Print ISSN: 1452-8258 (Print) Linking ISSN: 14528266 NLM ISO Abbreviation: J Med Biochem Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: 2020- : Belgrade : Society of Medical Biochemists of Serbia Original Publication: Belgrade : Society of Medical Biochemists of Serbia |
| مستخلص: | Background: Tacrolimus is a widely used immunosuppressant that prevents solid organ transplant rejection. The pharmacokinetics of Tacrolimus show considerable varia - bility. Interleukin-10 (IL-10), in the host's immune response after transplantation, contributes to the variable CYP3Adependent drug disposition of Tacrolimus. In the current study, we aim to evaluate the impact of single nucleotide polymorphisms (SNP) in the promoter region of IL-10 on Tacrolimus dose requirements and the Dose Adjusted Concentration (DAC) of Tacrolimus among kidney transplantation recipients. Methods: Blood levels of Tacrolimus were measured using Microparticle Enzyme Immunoassay (MEIA) for six months post-transplantation. Genotyping analysis was utilized using specific Polymerase Chain Reaction (PCR) followed by sequencing methods for 98 Jordanian kidney transplant recipients. Results: Genotyping frequencies of IL-10 (-592) were (CC/CA/AA: 38, 46.7, 15.2%); IL-10 (-819) were (CC/CT/TT: 40.4, 44.1, 15.1%); and IL-10 (-1082) were (AA/AG/GG: 42.6, 44.7, 12.8%). The impact of IL-10 (-1082) on Tacrolimus DAC was gender dependent. Men carrying at least one A allele had significantly lower DAC than men carrying GG genotyping only in the first month post-transplantation 88.2±32.1 vs. 117.5±22.5 ng/mL per mg/kg/day, p=0.04 . Conclusions: Our current study showed that the interaction between gender and IL-10 -1082 affects Tacrolimus DAC in Jordanian kidney transplant recipients during the first month post-transplantation. Competing Interests: Conflict of Interest: The authors stated that they have no conflicts of interest regarding the publication of this article. (2022 Bara'ah Khaleel, Al-Motassem Yousef, Mazhar Salim Al-Zoubi, Muhammad Al-Ulemat, Ahmad A. Masadeh, Ali Abuhaliema, Khalid M. Al-Batayneh, Bahaa Al-Trad, published by CEON/CEES.) |
| References: | Immunol Rev. 2008 Dec;226:205-18. (PMID: 19161426) Eur J Immunogenet. 1997 Feb;24(1):1-8. (PMID: 9043871) Clin Chim Acta. 2007 Aug;383(1-2):133-9. (PMID: 17568575) Dis Markers. 2017;2017:7834035. (PMID: 28246425) Iran J Kidney Dis. 2016 May;10(3):156-63. (PMID: 27225724) Br Med Bull. 2013;106:117-34. (PMID: 23645842) Arch Intern Med. 2004 Jul 12;164(13):1373-88. (PMID: 15249346) N Engl J Med. 2004 Dec 23;351(26):2715-29. (PMID: 15616206) Eur J Clin Pharmacol. 2011 Aug;67(8):803-13. (PMID: 21359536) Transplant Proc. 2004 Mar;36(2 Suppl):25S-32S. (PMID: 15041303) Transplantation. 2003 Mar 15;75(5):711-7. (PMID: 12640314) Am J Transplant. 2011 Oct;11(10):2093-109. (PMID: 21883901) Cytokine. 2005 May 21;30(4):188-94. (PMID: 15863393) Diabetes. 2006 May;55(5):1529-33. (PMID: 16644716) Clin Pharmacol Ther. 2000 Jan;67(1):32-43. (PMID: 10668851) Br J Clin Pharmacol. 2007 Dec;64(6):750-7. (PMID: 17425625) Ther Drug Monit. 2009 Aug;31(4):416-35. (PMID: 19536049) PLoS One. 2014 Jan 21;9(1):e86206. (PMID: 24465960) Transplantation. 2010 Apr 15;89(7):851-7. (PMID: 20048695) J Am Soc Nephrol. 2001 Jan;12(1):201-204. (PMID: 11317972) Ann Intern Med. 2003 Jul 15;139(2):137-47. (PMID: 12859163) Am J Transplant. 2011 Nov;11(11):2279-96. (PMID: 21929642) Cold Spring Harb Perspect Med. 2014 Feb 01;4(2):. (PMID: 24370927) J Immunol. 2001 Mar 15;166(6):3915-22. (PMID: 11238636) BMC Med Genet. 2011 Jun 09;12:81. (PMID: 21658228) |
| فهرسة مساهمة: | Keywords: IL-10 genetic polymorphism; kidney transplantation; pharmacokinetics; tacrolimus Local Abstract: [Publisher, Serbian] Takrolimus je široko korišćen imunosupresiv koji sprečava odbacivanje presađenog čvrstog organa. Farmako-kinetika takrolimusa pokazuje značajnu varijabilnost interleukin-10 (IL-10), u imunološkom odgovoru domaćina nakon transplantacije, doprinosi promenljivoj dispoziciji leka zavisne od CIP3A kod takrolimusa. U ovoj studiji, cilj nam je da procenimo uticaj polimorfizama pojedinačnih nukleotida (SNP) u promotorskom regionu IL-10 na zahteve za dozom takrolimusa i koncentraciju prilagođenu dozi (DAC) takrolimusa među primaocima transplantacije bubrega. [Publisher, Serbian] Nivoi takrolimusa u krvi su mereni korišćenjem imunoeseja mikročestica enzima (MEIA) tokom šest meseci nakon transplantacije. Analiza genotipizacije je izvedena korišćenjem specifične lančane reakcije polimeraze (PCR) praćene metodama sekvenciranja za 98 jordanskih primalaca transplantiranih bubrega. [Publisher, Serbian] Učestalosti genotipizacije IL-10 (-592) su (CC/CA/AA: 38, 46,7, 15,2%); IL-10 (-819) su (CC/CT/TT: 40,4, 44,1, 15,1%); i IL-10 (-1082) su (AA/AG/GG: 42,6, 44,7, 12,8%). Uticaj IL-10 (-1082) na takrolimus DAC zavisio je od pola. Muškarci koji su nosili najmanje jedan alel A imali su značajno niži DAC od muškaraca koji su nosili genotipizaciju GG samo u prvom mesecu nakon trans plantacije 88,2±32,1 naspram 117,5±22,5 ng/mL po mg/kg/dan, p=0,04 . [Publisher, Serbian] Naša trenutna studija je pokazala da interakcija između pola i IL-10-1082 utiče na takrolimus DAC kod jordanskih primalaca transplantacije bubrega tokom prvog meseca nakon transplantacije. |
| تواريخ الأحداث: | Date Created: 20220831 Latest Revision: 20220906 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC9375538 |
| DOI: | 10.5937/jomb0-33343 |
| PMID: | 36042898 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1452-8258 |
|---|---|
| DOI: | 10.5937/jomb0-33343 |